Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT
Sponsor: Chinese PLA General Hospital
Summary
This is a multi-center, single arm, open-label, phase I study to determine the safety and effectiveness of EBV-TCR-T cell immunotherapy in treating EBV virus infection after allogenic HSCT.
Official title: Multicenter, Open Label, Single-arm Exploratory Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT
Key Details
Gender
All
Age Range
14 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2023-08-01
Completion Date
2028-12-31
Last Updated
2026-04-02
Healthy Volunteers
No
Conditions
Interventions
EBV-TCR-T cells
The patients with EBV infection after HSCT will receive one to three infusions of donor-derived EBV-TCR-T cells, with the escalated dose ranging from 5×10\^5/kg to 1×10\^6/kg EBV-TCR-T cells per dose.
Locations (1)
Chinese PLA General Hospital
Beijing, Beijing Municipality, China